2. Драпкина О.М., Концевая А.В., Калинина А.М. с соавт. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022; 21(4): 5–232. [Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. 2022 prevention of chronic non-communicable diseases in of the Russian Federation. National guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(4): 5–232 (In Russ.)].https://dx.doi.org/10.15829/1728-8800-2022-3235. EDN: DNBVAT.

3. Драпкина О.М., Шишкова В.Н., Котова М.Б. Психоэмоциональные факторы риска хронических неинфекционных заболеваний в амбулаторной практике. Методические рекомендации для терапевтов. Кардиоваскулярная терапия и профилактика. 2022; 21(10): 97–117. [Drapkina O.M., Shishkova V.N., Kotova M.B. Psychoemotional risk factors for non-communicable diseases in outpatient practice. guidelines for internists. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(10): 97–117 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2022-3438. EDN: SAGMPE.

4. Шишкова В.Н., Драницына Б.Г., Драпкина О.М. Алгоритмы ведения пациентов с тревогой в практике терапевта. Кардиоваскулярная терапия и профилактика. 2023; 22(2): 63–69. [Shishkova V.N., Dranitsyna B.G., Drapkina O.M. Algorithms for the management of patients with anxiety in the internist’s practice. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023; 22(2): 63–69 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2023-3526. EDN: NKQFOC.

5. Tong A., Wang X., Li F. et al. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: A meta-analysis of prospective cohort studies. Acta Diabetol. 2016; 53(4): 589–98.https://dx.doi.org/10.1007/s00592-016-0845-1.

6. Palmer S., Vecchio M., Craig J.C. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013; 84(1): 179–91. https://dx.doi.org/10.1038/ki.2013.77.

7. Xiao T., Qiu H., Chen Y. et al. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: A cross-sectional study. BMC Psychiatry. 2018; 18(1): 89.https://dx.doi.org/10.1186/s12888-018-1671-5.

8. Krebber A.M., Buffart L.M., Kleijn G. et al. Prevalence of depression in cancer patients: A meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014; 23(2): 121–30. https://dx.doi.org/10.1002/pon.3409.

9. Read J.R., Sharpe L., Modini M. et al. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017; 221: 36–46. https://dx.doi.org/10.1016/j.jad.2017.06.009.

10. Ronaldson A., de la Torre J.A., Prina M. et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. Lancet Reg Health Eur. 2021; 8: 100149. https://dx.doi.org/10.1016/j.lanepe.2021.100149.

11. Long D.J., Ouyang Y., Duan H. et al. Multiple factor analysis of depression and/or anxiety in patients with acute exacerbation chronic obstructive pulmonary. Int J Chron Obstruct Pulmon Dis. 2020; 15: 1449–64. https://dx.doi.org/10.2147/COPD.S245842.

12. Wen-Tao D., Xue-Xiu C., Zun-Jiang C. et al. The relationship between hospitalization frequency of acute exacerbation of chronic obstructive pulmonary disease and anxiety and depression. Front Genet. 2022; 13: 817727.https://dx.doi.org/10.3389/fgene.2022.817727.

13. Volpato E., Toniolio S., Pagnini F., Banfi P. The relationship between anxiety, depression and treatment adherence in chronic obstructive pulmonary disease: A systematic review. Int J Chron Obstruct Pulmon Dis. 2021; 16: 2001–21.https://dx.doi.org/10.2147/COPD.S313841.

14. Stallberg B., Janson C., Larsson K. et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018; 28(1): 33. https://dx.doi.org/10.1038/s41533-018-0101-y.

15. Zareifopoulos N., Bellou A., Spiropoulou A., Spiropoulos K. Prevalence, contribution to disease burden and management of comorbid depression and anxiety in chronic obstructive pulmonary disease: A narrative review. COPD. 2019; 16(5–6): 406–17.https://dx.doi.org/10.1080/15412555.2019.1679102.

16. Peyrot M., Rubin R.R., Lauritzen T. et al. Psychosocial problems and barriers to improved diabetes management: Results of the cross-national diabetes attitudes, wishes and needs (DAWN) study. Diabetes Med. 2005;22(10): 1379–85.https://dx.doi.org/10.1111/j.1464-5491.2005.01644.x.

17. Perrin N.E., Davies M.J., Robertson N. et al. The prevalence of diabetes-specific emotional distress in people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Med. 2017; 34(11): 1508–20. https://dx.doi.org/10.1111/ dme.13448.

18. Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: A meta-analysis. Diabetes Care. 2008; 31(12): 2383–90. https://dx.doi.org/10.2337/dc08-0985.

19. Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: Systematic literature review. Diabetes Med. 2006; 23(4): 445–48. https://dx.doi.org/10.1111/j.1464-5491.2006.01814.x.

20. Huang C.J., Hsieh H.M., Tu H.P. et al. Generalized anxiety disorder in type 2 diabetes mellitus: Prevalence and clinical characteristics. Braz J Psychiatry. 2020; 42(6): 621–29. https://dx.doi.org/10.1590/1516-4446-2019-0605.

21. Deschenes S., Burns R.J., Schmitz N. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: Findings from the 2012 Canadian Community Health Survey – Mental Health (CCHS-MH). Psychosom Res. 2015; 78(2): 137–42. https://dx.doi.org/10.1016/j.jpsychores.2014.11.023.

22. Asbjornsdottir B., Vestgaard M., Do N.C. et al. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Diabet Med. 2021; 38(3): e14506. https://dx.doi.org/10.1111/dme.14506.

23. Van der Feltz-Cornelis C., Allen S.F., Holt R.I.G. et al. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav. 2021; 11(2): e01981. https://dx.doi.org/10.1002/brb3.1981.

24. Winkley K., Upsher R., Stahl D. et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: A systematic review. Health Technol Assess. 2020; 24(28): 1–232. https://dx.doi.org/10.3310/hta24280.

25. Palmer S., Vecchio M., Craig J.C. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013; 84(1): 179–91. https://dx.doi.org/10.1038/ki.2013.77.

26. Stasiak C.E.S., Bazan K.S., Kuss R.S. et al. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014; 36(3): 325–31. https://dx.doi.org/10.5935/0101-2800.20140047.

27. Nagler E.V., Webster A.C., Vanholder R., Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012; 27(10): 3736–45. https://dx.doi.org/10.1093/ndt/gfs295.

28. Chilcot J., Farrington K. The case for selective withdrawal of antidepressants in patients with advanced kidney disease. J Am Soc Nephrol 2019; 30(7): 1339–40. https://dx.doi.org/10.1681/ASN.2019030308.

29. Wasteson E. Mood disorders in patients with cancer. Lancet Oncol. 2011; 12(2): 114–15.https://dx.doi.org/10.1016/S1470-2045(11)70007-9.

30. Krebber A.M.H., Buffart L.M., Kleijn G. et al. Prevalence of depression in cancer patients: Meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014; 23(2) :121–30. https://dx.doi.org/10.1002/pon.3409.

31. Wang Y.H., Li J.Q., Shi J.F. et al. Depression and anxiety in relation to cancer incidence and mortality: A systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020; 25(7): 1487–99. https://dx.doi.org/10.1038/s41380-019-0595-x.

32. Celano C.M., Millstein R.A., Bedoya C.A. et al. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015; 170(6): 1105–15. https://dx.doi.org/10.1016/j.ahj.2015.09.013.

33. Шишкова В.Н., Устарбекова Д.Б., Шишков В.А. с соавт. Психоэмоциональные нарушения у пациентов с хронической сердечной недостаточностью. Терапия. 2022; 8(1): 44–49. [Shishkova V.N., Ustarbekova D.B., Shishkov V.A. et al. Psycho-emotional disorders in chronic heart failure patients. Terapiya = Therapy. 2022; 8(1): 44–49 (In Russ.)].https://dx.doi.org/10.18565/therapy.2022.1.44-49. EDN: JKEKXX.

34. Vaccarino V., Badimon L., Bremner J.D. et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020; 41(17): 1687–96. https://dx.doi.org/10.1093/eurheartj/ehy913.

35. Daskalopoulou M., George J., Walters K. et al. Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: Data linkage study of 1.9 million women and men. PLoS One. 2016; 11(4): e0153838.https://dx.doi.org/10.1371/journal.pone.0153838.

36. Peters A., McEwen B.S. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015; 56: 139–50. https://dx.doi.org/10.1016/j.neubiorev.2015.07.001.

37. Albus C., Waller C., Fritzsche K. et al. Significance of psychosocial factors in cardiology: Update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019; 108(11): 1175–96. https://dx.doi.org/10.1007/s00392-019-01488-w.

38. Smyth A. Physical activity and anger or emotional upset as triggers of acute myocardial infarction: The INTERHEART study. Circulation. 2016; 134(15): 1059–67. https://dx.doi.org/10.1161/CIRCULATIONAHA.116.023142.

39. Евстифеева С.Е., Шальнова С.А., Макарова Ю.К. с соавт. Ассоциируется ли уровень тревоги и депрессии в популяции со смертностью населения? По данным исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2021; 20(5): 252–261. [Evstifeeva S.E., Shalnova S.A., Makarova Yu.K. et al. Is the population level of anxiety and depression associated with mortality? Data from the ESSE-RF study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2021; 20(5): 252–261 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2021-3009. EDN: LCPZLS.

40. Moise N., Khodneva Y., Jannat-Khah D.P. et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: The REGARDS study. BMJ Open. 2018; 8(1): e017385. https://dx.doi.org/10.1136/bmjopen-2017-017385.

41. Ye S., Muntner P., Shimbo D. et al. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: The REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013; 61(6): 622–30. https://dx.doi.org/10.1016/j.jacc.2012.09.058.

42. Tully P.J., Cosh S.M., Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014; 77(6): 439–48. https://dx.doi.org/10.1016/j.jpsychores.2014.10.001.

43. Thompson D.R., Ski S.F. Psychosocial interventions in cardiovascular disease – what are they? Eur J Prev Cardiol. 2013; 20(6): 916–17. https://dx.doi.org/10.1177/2047487313494031.

44. Pizzi C., Rutjes A.W., Costa G.M. et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011; 107(7): 972–79. https://dx.doi.org/10.1016/j.amjcard.2010.11.017.

45. He W., Zhou Y., Ma J. et al. Effect of antidepressants on death in patients with heart failure: A systematic review and meta-analysis. Heart Fail Rev. 2020; 25(6): 919–26. https://dx.doi.org/10.1007/s10741-019-09850-w.

46. Honkola J., Hookana E., Malinen S. et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012; 33(6): 745–51. https://dx.doi.org/10.1093/eurheartj/ehr368.

47. Шишкова В.Н. Стратегия ведения и профилактики психоэмоциональных нарушений в практике терапевта. Медицинский совет. 2023; 17(6): 76–82. [Shishkova V.N. Strategy for the management and prevention of psycho-emotional disorders in the GP’s practice. Meditsinskiy sovet = Medical Council. 2023; 17(6): 76–82 (In Russ.)]. https://dx.doi.org/10.21518/ms2023-077. EDN: ZUOVBB.

48. Вейн А.М., Артеменко А.Р., Онкин В.Ю. с соавт. Эффективность грандаксина в коррекции психовегетативных расстройств. Лечение нервных болезней. 2001: 9–20. [Vein A.M., Artemenko A.R., Onkin V.Yu. et al. The effectiveness of grandaxin in the correction of psychovegetative disorders. Lecheniye nervnykh bolezney = Treatment of Nervous Diseases. 2001: 9–20 (In Russ.)].

49. Стаценко М.Е., Говоруха О.А. Влияние грандаксина на показатели качества жизни и темп реабилитации больных с сердечной недостаточностью, перенесших инфаркт миокарда. Южно-Российский медицинский журнал. 2003; (5–6): 13–21. [Statsenko M.E., Govoruha O.A. Influence of grandaxin on indicators of quality of life and rate of rehabilitation of patients with heart failure after myocardial infarction. Yuzhno-Rossiyskiy meditsinskiy zhurnal = Southern Russian Medical Journal. 2003; (5–6): 13–21 (In Russ.)]. EDN: WQUWXL.

50. Кулешова Э.В. Применение тофизопама (грандаксина) для лечения больных ишемической болезнью сердца. Клиническая фармакология и терапия. 2000; 9(5): 53–55. [Kuleshova E.V. The use of tofisopam (grandaxin) for the treatment of patients with coronary heart disease. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2000; 9(5): 53–55 (In Russ.)].

51. Осипенко М.Ф., Храмов Ю.Л., Макарова Т.А. с соавт. Роль грандаксина в лечении функциональных заболеваний желудочно-кишечного тракта. Терапевтический архив. 2000; 72(10): 23–27. [Osipenko M.F., Khramov Yu.L., Makarova T.A. et al. The role of grandaxin in the treatment of functional diseases of the gastrointestinal tract. Terapevticheskiy arkhiv = Therapeutic Archive. 2000; 72(10): 23–27 (In Russ.)].

52. Гольдин Б.Г., Савицкая И.В. Грандаксин в лечении тревожных расстройств у больных бронхиальной астмой. В мире лекарств: клиническая фармакология и фармакотерапия. 1999; (3–4): 82–84. [Goldin B.G., Savitskaya I.V. Grandaxin in the treatment of anxiety disorders in patients with bronchial asthma. V mire lekarstv: klinicheskaya farmakologiya i farmakoterapiya = In the World of Medicines: Clinical Pharmacology and Pharmacotherapy. 1999; (3–4): 82–84 (In Russ.)]. EDN: YQBKXD.